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a  b  s  t  r  a  c  t
Anthrax  Vaccine  Adsorbed  (AVA,  BioThrax®) is approved  for use  in  humans  as  a priming  series  of  3
intramuscular  (i.m.)  injections  (0, 1, 6  months;  3-IM)  with  boosters  at 12 and  18  months,  and  annually
thereafter  for those  at continued  risk  of  infection.  A reduction  in  AVA  booster  frequency  would  lessen
the  burden  of  vaccination,  reduce  the cumulative  frequency  of  vaccine  associated  adverse  events  and
potentially  expand  vaccine  coverage  by requiring  fewer  doses  per  schedule.  Because  human  inhalation
anthrax  studies  are  neither  feasible  nor  ethical,  AVA  efﬁcacy  estimates  are  determined  using cross-species
bridging  of  immune  correlates  of  protection  (COP)  identiﬁed  in  animal  models.  We  have  previously
reported  that  the  AVA  3-IM priming  series  provided  high  levels  of protection  in  non-human  primates
(NHP)  against  inhalation  anthrax  for  up  to 4 years  after  the  ﬁrst  vaccination.  Penalized  logistic  regressions
of  those  NHP  immunological  data  identiﬁed  that  anti-protective  antigen  (anti-PA)  IgG concentration
measured  just  prior  to infectious  challenge  was  the most  accurate  single  COP.
In  the  present  analysis,  cross-species  logistic  regression  models  of this  COP  were  used  to predict  proba-
bility  of survival  during  a 43  month  study  in  humans  receiving  the  current  3-dose  priming  and  4 boostersnimal model
(12,  18,  30  and  42  months;  7-IM)  and  reduced  schedules  with  boosters  at months  18  and  42  only  (5-IM),
or  at  month  42  only  (4-IM).  All  models  predicted  high  survival  probabilities  for  the  reduced  schedules
from  7  to  43 months.  The  predicted  survival  probabilities  for the  reduced  schedules  were  86.8%  (4-IM)
and  95.8%  (5-IM)  at month  42  when  antibody  levels  were  lowest.  The  data  indicated  that  4-IM  and  5-IM
are  both  viable  alternatives  to  the  current  AVA  pre-exposure  prophylaxis  schedule.
Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC BY-NC-ND  license  (http://Abbreviations: AE, adverse events; AUC, area under the receiving operator char-
cteristic curve; AVA, Anthrax Vaccine Adsorbed; AVRP, Anthrax Vaccine Research
rogram; CDC, Centers for Disease Control and Prevention; COP, correlates of
rotection; ED50, effective dilution for 50% neutralization; FDA, Food and Drug
dministration; GCP, Good Clinical Practices; IACUC, Institutional Animal Care and
se Committee; i.m., intramuscular; IND, Investigational New Drug; LLOD, lower
imit of detection; LLOQ, lower limit of quantiﬁcation; NHP, non-human primate;
A, protective antigen; s.c., subcutaneous; TNA, toxin neutralization activity; VE,
accine effectiveness.
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1 Current address: Department of Epidemiology, University of Alabama at Bir-
ingham, LHL 440, 1720 2nd Ave South, Birmingham, AL 35294, United States.
2 Current address: 4805 Ruby Forrest Drive, Stone Mountain, GA 30083, United
tates.
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264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-Ncreativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The US licensed anthrax vaccine adsorbed (AVA, BioThrax®)
was approved in 1970 for prevention of anthrax in humans
[1–3]. The primary immunogen in AVA is anthrax toxin protective
antigen (PA) [4]. The 1970 regimen for AVA was a subcuta-
neous (s.c.) six-dose primary schedule at 0, 0.5, 1, 6, 12 and
18 months with subsequent annual boosters. In May  2012, the
US Food and Drug Administration (FDA) approved a revised
AVA schedule with an intramuscular (i.m.) three-dose primary
schedule at months 0, 1, 6 (3-IM), with boosters at months
12 and 18 followed by annual boosters for those at contin-
ued risk of infection (http://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm304758.htm). The public health
impact of these changes resides in the signiﬁcant reduction in
the frequency, severity and duration of local adverse events with
i.m. administration, the elimination of the injection at week 2 and
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mmunological protection acquired with the administration of the
hird dose at month 6 rather than after the sixth dose at month
8. Nonetheless, the AVA booster schedule retains a relatively high
urden of injections compared to many other vaccines [5,6].
Studies by Pittman and coworkers have demonstrated that
ncreasing the intervals between doses of AVA can increase the
ntibody response to booster vaccinations [6–8]. Similar conclu-
ions were reported in the CDC Anthrax Vaccine Research Program
AVRP) phase 4 human clinical trial [3,9]. The CDC AVRP demon-
trated that study participants receiving the 3-IM priming series
ith boosters at months 18 and 42 (5-IM) or only at month 42
4-IM) developed signiﬁcantly higher levels of anti-PA antibod-
es at months 19 (5-IM group) and 43 (4-IM and 5-IM groups)
ompared to those receiving annual boosters (7-IM). These dif-
erences were particularly striking in the group receiving only the
onth 42 booster (4-IM), which achieved post-boost antibody con-
entrations twice as high as the original licensed 8-SC schedule
433.2 g/mL vs. 216.8 g/mL). These data in humans indicated
hat immunological priming by AVA was long-lasting and robust
ith the ability to produce a high magnitude anamnestic response
p to at least 3 years after 3-IM priming [9].
The 3-IM priming schedule without boosters has also been
emonstrated to provide long term protection up to 4 years in
hesus macaques [10]. Chen et al. subsequently applied penal-
zed logistic regression models to the NHP humoral and cellular
mmunological response proﬁles to select the most predictive
mmune correlates of protection (COP) [11]. The most accurate
ingle COP was the serum anti-protective antigen (anti-PA) IgG
oncentration at the time of infectious challenge. Additional
OP with good predictive power included peak anti-PA IgG
oncentrations and lethal toxin neutralization activity (TNA)
iters at month 7, and dual-correlate models that combined
ne peak measurement (anti-PA IgG or TNA ED50) and anti-
A IgG at challenge [11]. The COP are considered pivotal for
ross-species predictions of anthrax vaccine efﬁcacy in humans
here clinical efﬁcacy studies are impractical and ethically
nfeasible ([12,13], http://www.fda.gov/AdvisoryCommittees/
ommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/
accinesandRelatedBiologicalProductsAdvisoryCommittee/
cm239733.htm).
The objective of the current report was to determine the feasi-
ility of reduced AVA booster schedules in humans. We  describe
ridging of the NHP anti-PA IgG and TNA ED50 COP to the CDC
VRP human study data using logistic regression models to gener-
te predicted survival probabilities provided by annual and reduced
ooster schedules [13]. Distinct from the previous non-inferiority
able 1
chedule of intramuscular vaccination for The Human and NHP Study Groups in the AVRP
Primary
series
(months)
Booster
schedule
(months)
Study
group
Month
0
Month
0.5
Mont
1
Human 0, 1, 6 12, 18, 30, 42 7-IM AVA Saline AVA 
0,  1, 6 18, 42 5-IM AVA Saline AVA 
0,  1, 6 42 4-IM AVA Saline AVA 
NHP 0,  1, 6 None Human
dose
AVA No
injection
AVA 
1:5 AVA No
injection
AVA 
1:10 AVA No
injection
AVA 
1:20 AVA No
injection
AVA 
1:40 AVA No
injection
AVA 
he human and NHP studies have been described in detail previously [9,10]. At each time
iluted doses of AVA (undiluted, 1/5, 1/10, 1/20 or 1/40) at months 0, 1 and 6. Subsets of 3 (2015) 3709–3716
analysis of peak responses to vaccination, this study provides a spe-
ciﬁc focus on determining survival probabilities during the periods
of receding and lowest antibody levels between the completion of
the priming series and the subsequent booster vaccinations. This is
the ﬁrst report of a bridging analysis between the CDC nonhuman
primate correlates of protection data with the CDC AVRP human
clinical trial.
2. Materials and methods
2.1. Human and NHP data sets
Study schedules for humans and NHP are summarized in Table 1.
The human data sets were from the CDC AVRP clinical trial com-
prising 1563 human participants as previously reported [9]. Three
study arms (7-IM, 5-IM, and 4-IM, Table 1) received i.m. prim-
ing doses at 0, 1 month, and 6 months, matching the NHP cohort
schedule. After completion of priming, the study groups received
annual or alternate booster schedules: 7-IM received the complete
schedule of boosters at month 12, 18, 30 and 42; 5-IM received
booster doses at months 18 and 42; and 4-IM received a single
booster at month 42. Serum anti-PA IgG antibodies were quanti-
ﬁed in all participants that were According to Protocol (ATP) for
immunogenicity [9]. TNA ED50 was  obtained for a subset of approx-
imately 46% of the ATP participants. The study was sponsored by
CDC under an Investigational New Drug (IND) application, was
approved by the human investigations committees at participat-
ing clinical sites and at CDC, and was conducted according to the
International Conference on Harmonization Good Clinical Practices
(GCP) (www.clinicaltrials.gov; NCT00119067).
The NHP study has been reported in detail by Quinn et al. [10]
and Chen et al. [11]. Chen et al. identiﬁed serum anti-PA IgG con-
centrations at the time of challenge (last) as the most accurate
immunological COP for 3-IM priming in rhesus macaques. Addi-
tional correlates with good predictive power included peak anti-PA
IgG concentrations and lethal toxin neutralization activity (TNA)
titers at month 7 (peak), and dual-correlate models that combined
one peak measurement (anti-PA IgG or TNA ED50) and last anti-PA
IgG [11].
2.2. Bridging from NHP to humansThe method for bridging a non-human COP to predict
survival probability in humans was  described by Fay et al.
[13] and Kohberger et al. [14] and in http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/
 Study.
h Month
6
Month
12
Month
18
Month
30
Month
42
Month
52
AVA AVA AVA AVA AVA N/A
AVA Saline AVA Saline AVA N/A
AVA Saline Saline Saline AVA N/A
AVA No
injection
No
injection
Challenge
(subset)
No
injection
Challenge
AVA No
injection
No
injection
Challenge
(subset)
No
injection
Challenge
AVA Challenge
(subset)
No
injection
Challenge
(subset)
No
injection
Challenge
AVA Challenge
(subset)
No
injection
Challenge NA NA
AVA Challenge NA NA NA NA
 point, humans received either a full dose of AVA or a saline placebo. NHP received
NHP were challenged at months 12, 30 and 52 [10,11].
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Fig. 1. Predicted probability of human survival at month 42 in the Minimum Schedule 4-IM Study Group using a single-correlate model with last anti-PA IgG. NHP survivors
()  (1.0 on the Y-axis) and non-survivors (©) (0 on the Y-axis) are plotted with slight vertical Y-axis displacements so that overlapping points may  be seen. NHP  immune
response data were binned by anti-PA IgG concentration range; bin 1 > LLOD (0.4 g/mL); bin 2 LLOD to LLOQ (2.3 g/mL); remaining bins contain NHP with anti-PA IgG in
2-fold  increases above the LLOQ (e.g. ≥2.3 to <4.6, ≥4.6 to <9.2, etc.). Key: (—) logistic regression curve of predicted survival based on the NHP last anti-PA IgG measurements;
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the cost of lower statistical power due to the smaller NHP groups.)  mean survival of NHP binned by anti-PA IgG concentration; () individual hum
rior  to receiving the booster vaccination, also shown with slight vertical Y-axis dis
ndividual human subjects; (→) mean predicted probability of survival for the hum
loodVaccinesandOtherBiologics/VaccinesandRelatedBiological
roductsAdvisoryCommittee/UCM232400.pdf. The method has
een applied here to predict survival in humans using the NHP
OP models. Using PROC LOGISTIC in SAS® version 9.3.1 the NHP
ata were ﬁtted to the logistic regression model:
r (survive) = 1(
1 + exp
(
−  ˛ − ˇx
))
where  ˛ is the intercept,  is the vector of slope parameters,
nd x is the vector of measured correlates. Predicted human sur-
ival probability (Pr(survive)) was then calculated for each human
ndividual using the  ˛ and  parameters estimated by the NHP sur-
ival data and the measured correlates (x) of the humans. The mean
f the predicted survival probabilities of all the humans in each
ooster reduction group was taken as the overall predicted survival
robability for that booster schedule (see Fig. 1 for illustration of
ingle-correlate bridging and Fig. 2 for illustration of dual-correlate
ridging). Difference tests between groups were performed on the
redicted survival probabilities with an alpha of 0.05. Conﬁdence
ntervals were calculated using a non-parametric double-bootstrap
ethod by resampling both the NHP and human datasets 2000
imes, calculating mean predicted survival probability for each
esample, sorting these from lowest to highest and taking the 50th
nd 1950th resamples as the 95% conﬁdence intervals [13,15].
The NHP anti-PA IgG ELISA had a lower limit of detection (LLOD)
f 1.7 g/mL for humans and 0.4 g/mL for NHP and a lower limit
f quantiﬁcation (LLOQ) of 3.7 g/mL for humans and 2.3 g/mL for
HP [10,16]. The TNA assay is considered to be species neutral and
ad a LLOD ED50 = 11 and lower LLOQ ED50 = 36 using reference
tandard AVR801 [17]. For logistic regression analyses using data
rom these assays all values below the LLOD were masked as 1/2
LOD for that assay and species.ti-PA IgG responses from the 4IM study group measured at month 42 immediately
ent so that overlapping points may be seen; (—) mapping of predicted survival for
M cohort at month 42.
For all models using a last variable, the result from the time
at which survival probability is predicted was used as the last
response (e.g. for prediction of survival probability at month 18, the
anti-PA IgG measured at month 18 is assigned to the last anti-PA
IgG variable in the model, etc.). Within the human data, analyses of
single correlate models at the month 7 peak were done by combin-
ing the 7-IM, 5-IM and 4-IM study group data since their treatment
up to that time point was the same, and no signiﬁcant differences
in anti-PA IgG or TNA ED50 were seen between those groups at
that time [9]. For analyses that included later time points when
the booster schedules differed, the study groups were analyzed
independently.
2.3. Single and dual correlate models
Single correlate models used a single time point in the NHP
immunological response time course to calculate probability of sur-
vival at speciﬁc time points in the human study schedule. Two
approaches were applied for single correlate models. In the ﬁrst
approach all of the NHP groups’ data were combined into one
dataset. The model used the last measured anti-PA IgG concentra-
tion before challenge regardless of challenge time. This approach
has the highest accuracy within the NHP dataset [11]. The sec-
ond approach adopted a more stringent model matching the last
anti-PA IgG measurements from NHP at the month 30 and 52
infectious challenge time points with the closest corresponding
serological response time points in humans. This approach most
closely matches all of the criteria recommended in Fay et al. [13] atDual-correlate models used peak anti-PA IgG or ED50 measured
at month 7 with last anti-PA IgG to incorporate both the response
to 3-IM priming and the serum antibody levels at the time of chal-
lenge.
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Fig. 2. Dual-correlate model surface plot mapping of predicted probability of survival at month 42 in the Human 4-IM Study Group. The surface grid illustrates the relationship
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ndividual humans from the 4-IM study group measured at month 42; (—) mappin
redicted survival probability for the human 4-IM cohort at month 42.
. Results
.1. Single correlate models
Using the combined last anti-PA IgG model (Fig. 1), the 4-IM,
-IM and 7-IM human study groups all attained similar high lev-
ls of predicted survival probability (96.7–97.3%) at month 12, the
ast time point prior to schedule divergence (Table 2). The subse-
uent focus of the analyses was on time points immediately prior
o injection at which one study schedule received a booster vac-
ination that a reduced schedule (saline injection) did not. These
ere study time points at which antibody levels, and consequently
he predicted survival probability, were lowest for each schedule. At
onth 18 the 4-IM and 5-IM study groups (no booster at month 12)
able 2
uman predicted survival probability at key study time points using the combined NHP s
Last anti-PA IgG (combined NHP groups)
4-IM 
Time point (months) NHP N Human N % Survival (95% CI) 
7 137 220 99.4 (98.0–99.9) 
12  137 215 96.9 (93.5–99.0) 
13  137 211 96.2* (92.6–98.5) 
18  137 201 93.3* (88.6–97.0) 
19  137 193 93.4*,† (88.6–96.8) 
30  137 182 89.9*,† (84.7–94.3) 
31  137 179 89.4*,† (83.5–94.2) 
42  137 161 86.8 (80.8–92.1) 
43  137 157 99.7 (98.7–100.0) 
he NHP study and selection of COP have been described in detail previously [10,11]. Con
§ Time points where boosters were administered.
* Statistically signiﬁcant difference from the 7-IM group.
† Statistically signiﬁcant difference from the 5-IM group. NHP survival data. Key: (|) mapping of peak ED50 and last anti-PA IgG response of
mune response to predicted survival probability from the surface grid; (→) mean
maintained a predicted survival probability of 93.3%, compared to
98.3% for the 7-IM group (booster at month 12). At month 30, both
7-IM and 5-IM groups were 1 year post-boost but the 4-IM group
had not been boosted (Table 1). At this time point the 5-IM and 7-
IM groups attained 97.1% and 97.2% predicted survival probability,
respectively, compared to 89.9% for the 4-IM group. At month 42
the 7-IM study group was  1 year post-boost (month 30), the 5-IM
group was 2 years post-boost (month 18) and the 4-IM group was
3 years post-priming (month 6). At this study time point, just prior
to the last scheduled injection, the 4-IM and 5-IM groups attained
86.8% and 95.8% predicted survival probability, respectively, com-
pared to 98.1% for the 7-IM group. At month 43, the ﬁnal study time
point 4 weeks after all groups received a booster dose, all groups
were between 99.6% and 99.8% predicted survival probability.
ingle correlate last anti-PA IgG model.
5-IM 7-IM
Human N % Survival (95% CI) Human N % Survival (95% CI)
202 99.3 (97.8–99.9) 214 99.5 (98.3–99.9)
197 96.7 (93.4–98.8) 211 97.3§ (94.2–99.2)
188 96.3* (9254–98.5) 203 99.7 (98.4–100.0)
179 93.3§ , * (88.3–97.1) 194 98.3§ (95.3–99.6)
174 99.7 (98.6–100.0) 192 99.6 (98.4–99.9)
162 97.1 (93.8–98.9) 179 97.2§ (93.7–99.2)
153 96.9* (93.4–98.9) 169 99.7 (98.8–100.0)
145 95.8§ , * (91.6–98.5) 147 98.1§ (94.9–99.5)
141 99.7 (98.5–100.0) 139 99.7 (98.5–100.0)
ﬁdence intervals (95% CI) are in parentheses.
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Table  3
Human predicted survival probability at key study time points using the challenge time matched NHP single correlate last anti-PA IgG model.
Last anti-PA IgG (NHP groups matched by challenge time)
4-IM 5-IM 7-IM
Time point
(Months)
NHP N Human N % Survival (95% CI) Human N % Survival (95% CI) Human N % Survival (95% CI)
12 73 215 93.8 (81.3–99.0) 197 93.6 (81.3–98.7) 211 94.4§ (82.2–99.3)
30  58 182 93.4*,† (86.1–99.6) 162 98.6 (95.5–99.9) 179 99.0§ (95.7–100.0)
42  52 161 90.2§ , * ,† (81.1–97.9) 145 98.0§ (93.6–99.8) 147 99.5§ (96.8–100.0)
The human and NHP studies have been described in detail previously [9,10]. Only NHP with matched challenge time plus all controls were used for the model. Conﬁdence
intervals (95% CI) are in parentheses.
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* Statistically signiﬁcant difference from the 7-IM group.
† Statistically signiﬁcant difference from the 5-IM group.
Applying the more stringent models using only the last anti-
A IgG measurements from animals at challenge and the matching
ime points in humans generated slightly increased predicted sur-
ival probabilities at month 30 and 42 (Table 3). At month 12, the
-IM, 5-IM and 7-IM human study group attained similar high lev-
ls of predicted survival probability, from 93.6% to 94.4%. At month
0, the 7-IM human study group attained 99.0% predicted survival
robability, the 5-IM attained 98.6%, and the 4-IM attained 93.4%.
t month 42, prior to receiving the ﬁnal booster vaccination, the
-IM human study group attained 99.5% predicted survival proba-
ility, the 5-IM group attained 98.0%, and the 4-IM group attained
0.2%.
Predicted survival probabilities calculated using the single-
orrelate peak anti-PA IgG and ED50 models were the lowest
stimates of subsequent protection against inhalation anthrax for
ll schedules combined (754-IM, Table 4). The peak anti-PA IgG
odel indicated a predicted survival probability of 83.4%, and
he peak TNA model indicated a predicted survival probability of
9.3%.
. Dual correlate models
Predicted survival probability estimates from dual-correlate
odels ranged from 96.2% to 96.8% using peak anti-PA IgG with
ast anti-PA IgG and 95.4 to 96.6% using peak ED50 with last
nti-PA IgG (Table 5). At month 18, the 4-IM and 5-IM study groups
ttained predicted survival probabilities of 93.0% and 92.8% using
eak anti-PA IgG with last anti-PA IgG and 92.2% and 93.4% using
eak ED50 with last anti-PA IgG. The 7-IM study group attained
redicted survival probabilities of 97.8% using peak anti-PA IgG
ith last anti-PA IgG and 97.5% using peak ED50 with last anti-PA
gG. At month 30, the 4-IM study group attained predicted survival
robabilities of 89.8% using peak anti-PA IgG with last anti-PA
gG, and 89.0% using peak ED50 with last anti-PA IgG. The 5-IM
nd 7-IM study groups attained predicted survival probabilities of
6.5% and 96.7% using peak anti-PA IgG with last anti-PA IgG and
6.4% and 96.4% using peak ED50 with last anti-PA IgG. At month
2, the 4-IM study group attained predicted survival probabilities
f 87.1% using peak anti-PA IgG with last anti-PA IgG, and 85.1%
sing peak ED50 with last anti-PA IgG. The 5-IM and 7-IM study
able 4
uman predicted survival probability at month 7 using the single correlate peak anti-PA 
Peak anti-PA IgG 
754-IM 
Time point (Months) NHP N Human N 
7 137 636 
he human and NHP studies have been described in detail previously [9,10]. Predicted % su
nd  4-IM groups were combined as 754-IM since they received the same treatment at thigroups attained predicted survival probabilities of 95.2% and 97.5%
using peak anti-PA IgG with last anti-PA IgG and 95.7% and 97.4%
using peak ED50 with last anti-PA IgG. At month 43 (1 month
post-boost for all groups), all groups achieved 99.5% predicted
survival probability by both models (Table 5).
5. Discussion
5.1. Reduced booster schedules
Simpler and better tolerated regimens for AVA vaccination are
needed [5,6]. A reduction in the AVA booster schedule would be
signiﬁcant progress toward this goal. The change in route from
s.c. to i.m. signiﬁcantly reduced the rate of adverse reactions, but
mild to moderate local adverse reactions still occur in ∼50% of
the recipients (primarily tenderness and erythema), and mild sys-
temic reactions occur in ∼10% of recipients (primarily fatigue and
headache) [9]. Human safety and immunogenicity studies have
demonstrated that i.m. vaccination and increasing the interval
between booster doses have signiﬁcant potential to improve the
clinical proﬁle of the vaccine and reduce the AVA schedule with-
out compromising safety and immunogenicity [6–9]. Reducing the
booster schedule is anticipated to reduce the cumulative occur-
rence of adverse events (AE) per person-year of vaccine coverage
due to the reduced number of doses.
Human inhalation anthrax studies for vaccine efﬁcacy are
neither feasible nor ethical. Consequently, an assessment of AVA
efﬁcacy in humans is dependent on the COP determined from
animal studies together with probability of survival determina-
tions from cross-species bridging using statistical models [12,13].
Studies in NHP have demonstrated that a 3-dose i.m. priming
series alone (3-IM) provided high levels of protection (60 to 100%)
for up to 4 years against high level exposures to B. anthracis Ames
strain spores. Exposure to aerosolized spores stimulated rapid and
high anamnestic responses in 3-IM vaccinated NHP, indicative
of enduring immunological memory [10]. Statistical modeling of
NHP data demonstrated that serum anti-PA IgG concentration at
the time of challenge was  the most accurate single immune COP
for determining probability of survival against inhalation anthrax.
In the absence of a last anti-PA IgG measurement concurrent
IgG and ED50 models.
Peak ED50
754-IM
% Survival (95% CI) Human N % Survival (95% CI)
83.4 (76.2–89.2) 289 79.3 (72.1–85.7)
rvival in human cohorts based on the NHP peak anti-PA IgG model. The 7-IM, 5-IM
s month 7 time point. Conﬁdence intervals (95% CI) are in parentheses.
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Table 5
Human predicted survival probability at key study time points using a NHP dual correlate peak and last model.
Peak anti-PA IgG, last anti-PA IgG Peak ED50, last anti-PA IgG
4-IM 5-IM 7-IM 4-IM 5-IM 7-IM
Time point
(months)
NHP
N
Human
N
% Survival
(95% CI)
Human
N
%  Survival
(95% CI)
Human
N
%  Survival
(95% CI)
Human
N
%  Survival
(95% CI)
Human
N
%  Survival
(95% CI)
Human
N
%  Survival
(95% CI)
7 137 220 99.1 (95.4–99.9) 202 99.0 (95.0–99.8) 214 99.3 (95.9–99.9) 99 98.7 (94.5–99.9) 88 99.2 (95.0–99.9) 102 99.2 (95.4–99.9)
12  137 210 96.3 (91.2–98.8) 192 96.2 (90.9–98.7) 206 96.8§ (91.7–99.1) 94 95.4 (88.7–98.7) 82 96.6 (90.4–99.2) 98 96.4§ (90.2–99.1)
13  137 206 95.7* (90.7–98.3) 184 95.6* (90.1–98.7) 198 99.4 (96.4–100.0) 90 95.2* (88.7–98.5) 79 95.8* (89.4–98.8) 94 99.4 (95.5–100.0)
18  137 197 93.0* (87.5–96.7) 175 92.8§ , * (87.2–96.8) 189 97.8§ (93.2–99.6) 85 92.2* (85.7–96.6) 73 93.4§ , * (86.9–97.4) 89 97.5§ (91.7–99.5)
19  137 189 93.0*,† (87.8–96.7) 170 99.5 (96.6–100.0) 187 99.4 (96.4–99.9) 81 92.3*,† (85.4–96.8) 70 99.5 96.2–100.0) 87 99.4 (95.6–100.0)
30  137 178 89.8*,† (84.5–94.4) 159 96.5 (91.4–98.8) 175 96.7§ (91.7–99.1) 76 89.0*,† (82.2–94.5) 65 96.4 (90.5–99.1) 82 96.4§ (90.4–99.1)
31  137 175 89.4*,† (83.6–94.3) 150 96.4* (91.4–98.9) 166 99.5 (97.0–100.0) 74 87.7*,† (81.7–93.6) 62 96.5* (91.0–99.3) 76 99.5 (96.3–100.0)
42  137 158 87.1§ , * ,† (81.1–92.5) 142 95.2§ , * (89.9–98.3) 143 97.5§ (92.8–99.5) 68 85.1§ , * ,† (78.0–91.5) 58 95.7§ (89.4–98.9) 64 97.4§ (91.1–99.5)
43  137 154 99.5 (96.8–100.0) 138 99.5 (96.6–100.0) 135 99.5 (97.0–100.0) 64 99.5 (96.2–100.0) 55 99.5 (96.0–100.0) 58 99.5 (96.2–100.0)
Predicted % survival in human cohorts based on the NHP dual-correlate models (peak anti-PA IgG and last anti-PA IgG, or peak ED50 and last anti-PA IgG). All 137 NHP  were used for the model. Conﬁdence intervals (95% CI) are
in  parentheses.
§ Time points where boosters were administered.
* Statistically signiﬁcant difference from the 7-IM group.
† Statistically signiﬁcant difference from the 5-IM group.
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ith aerosol exposures in NHP, the month 7 anti-PA IgG and TNA
esponses to 3-IM priming were suitable alternative COP [11].
Fay et al. [13] identiﬁed four aspects of vaccine studies that
hould be matched as closely as possible between human and
nimal study data when bridging between genera: vaccine for-
ulation, vaccination schedule, the time of immune response
easurement and the time of challenge. The AVRP human and NHP
tudies both used AVA as the vaccine, and both used a 0, 1, 6 month
3-IM) priming schedule [9,10]. The NHP study design included an
ntentional imbalance of study group assignments and 3 different
hallenge times (months 12, 30 and 52), with the higher AVA dilu-
ion groups (less antigen per vaccine dose) being challenged early
nd the lower dilution groups being challenged later in the study
Table 1). In order to most closely match all of these aspects, pre-
icted probabilities of human survival at months 12 and 30 were
ased on the animals challenged at those time points. Predicted
robability of human survival at month 42 was based on animals
hallenged at month 52, the closest matching time point available.
onth 18, the time point at which the 7-IM study group received
ts ﬁrst boost and the schedule diverges from the 4-IM and 5-IM
roups, does not have a corresponding challenge time point in the
HP data set.
In addition to using the more restrictive matching, and in order
o make optimal use of the available data, the last measurements
efore challenge at months 12, 30 and 52 were combined as the
ast anti-PA IgG variable and used for NHP logistic regressions. This
odel was based on the hypothesis that the circulating antibody at
he time of challenge is the best correlate and was  conﬁrmed as the
est single COP by the analysis of Chen et al. [11]. The subsequent
egression curve was used for all of the human study groups. The
uman anti-PA IgG measurement at a given time point was used to
redict probability of survival at that time point based on the com-
ined last anti-PA IgG NHP regression curve, simulating exposure
t that time point. The analysis in Chen et al. demonstrated that this
ariable performed with the highest accuracy (AUC = 0.821) within
he full NHP cohort [11].
The human serum antibody responses to 3-dose i.m. priming
ith AVA were analogous to those providing long-term protection
gainst inhalation anthrax in rhesus macaques ([9,10], unpublished
ata of authors). The cross-species meta-analysis by Fay et al.
howed that there are differences between species in the amount of
rotection per unit of antibody measured by the TNA assay, and this
ikely applies to the highly correlated anti-PA IgG antibody mea-
urement as well. The difference in protection per unit of anti-PA
gG (g/mL) between human and NHP is unknown; therefore no
nter-species adjustment factor has been introduced in these anal-
ses. The peak and last anti-PA IgG and peak TNA COP from NHP
ere used accordingly to assess the impact on predicted survival
robability in humans receiving reduced booster schedules of AVA
n a 43 month study.
The validated anti-PA IgG ELISA and TNA assays have both a
ower limit of detection (LLOD) and a lower limit of quantiﬁcation
LLOQ). The analysis used LLOD for the anti-PA IgG ELISA and the
NA assays. The LLOQ is based on pre-deﬁned performance charac-
eristics of accuracy and precision. Application of the lower LLOD
asking limit has the effect of distinguishing between low reactiv-
ty samples and negative samples, and subsequently stratiﬁes more
HP data at the low end of the range of responses. Use of the LLOD
esults in a better curve ﬁt—the AUC increases from 0.748 to 0.821
or the last anti-PA IgG model (unpublished data of authors). Only
0 out of 35 NHP below the LLOD survived (28.6%), while 31 out of
6 NHP between the LLOD and the LLOQ survived (67.4%). These
urvival rates are statistically signiﬁcantly different (p < 0.0001),
herefore it is more appropriate to stratify the data by application
f the LLOD mask. While results below the LLOQ may  have less
recision, these data clearly indicate correlation with protection.3 (2015) 3709–3716 3715
The antibody level ‘trough’ time points prior to administration
of booster vaccinations were of primary interest. The key ques-
tion is how reductions in serum antibody levels affect predicted
survival probabilities. Use of a model that includes a last mea-
surement is required to assess and compare protection at those
time points. The lowest observed antibody levels were at month 42
in the 4-IM group, but the predicted survival probability for 4-IM
remained high, ranging from 85.2% to 90.2% at month 42 contin-
gent on the model applied. In the 7-IM and 5-IM study groups the
trough antibody minimum predicted survival probability over the
study duration was also high at 97.2% and 93.3%, respectively.
5.2. Predicted survival probability vs. vaccine effectiveness
There are no empirical data on which to verify a quantitative
comparison between the predicted survival probability based on
the high-dose NHP challenge and human vaccine effectiveness (VE)
in naturally occurring, presumed low-dose exposures. Brachman
et al. reported 92.5% VE for a predecessor anthrax vaccine under an
annual booster schedule. The study evaluated unvaccinated work-
forces (samples size range 148 to 655) with ongoing exposure
to B. anthracis spores; annual case rates ranged from 0.6 to 1.8%
(mean 1.2%) [5]. In persons categorized as ‘high risk’ in the mill
environments the infection rate reached 6.1%. Exposures in those
environments were estimated at 21–2100 infectious particles per
8 hour day [18,19]. In agreement with the empirical data, mod-
elling of dose-responses for inhalation anthrax in humans by Toth
et al. [20] suggested that the low doses in the mill environments
had between 1% and 10% probability of infection. Recognizing that
predicted survival probability reported here is derived from a cross-
species model rather than empirical observations in humans, it is
encouraging to note the similarities between the predictions and
the reported VE.
There are clear differences between systemic anthrax and the
pathogenesis of other vaccine preventable diseases. Nonetheless,
the predicted survival probability for the reduced AVA schedules is
comparable to VE for several vaccines currently in use. For example,
the cholera vaccine has been estimated as having 62% efﬁcacy [21],
a large scale rotavirus vaccine trial found an efﬁcacy of 72% [22], and
the quadrivalent bacterial meningitis vaccine has a VE estimated at
80–85% [23].
In the quantitative models of the dose-response and time course
of inhalation anthrax in humans evaluated by Toth et al. the infec-
tion probability approached the 100% asymptote at a single-point
total exposure threshold of approximately 1.0 × 105 spores [19].
The logistic curves generated from the current NHP data were
from high-dose aerosol challenges (median 504 × LD50 equiva-
lents; 2.8 × 107 spores) [10], over 4 orders of magnitude higher than
the mill exposures from which human VE was  calculated and over
2 orders of magnitude higher than the 1.0 × 105 spores threshold
of Toth et al. [19]. Based on these analyses we propose that the
risk of infection from low dose exposures in the environments in
which pre-exposure use of AVA is recommended is signiﬁcantly
less than the risk from the extremely high doses in the animal
challenge model. COP modelling in NHP high-dose exposures mod-
els may  therefore overestimate the antibody levels required for
protection against naturally occurring anthrax in a pre-exposure
prophylaxis scenario. Consequently the predicted probabilities of
human survival derived from these data are likely to be signiﬁcant
underestimates of VE.6. Conclusions
The most accurate correlates of protection identiﬁed from non-
human primate challenge studies have been used to assess the
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evels of protection afforded by reduced booster schedules of AVA.
f primary interest are the trough antibody time points just before
oost. All schedules provided high probability of survival estimates
n humans at all time-points with all models. The lowest estimates
ere 85.1%–90.2% predicted survival in the 4-IM schedule at month
2; 3 years post-priming with no intervening boosters. The survival
redictions match well with the observed annual booster schedule
accine efﬁcacy of 92.5% [5]. In agreement with previous studies,
ncreasing the interval between boosters generated consistently
igher anamnestic responses [6–9]. These enhanced responses to
he reduced schedules, together with the sustained predicted sur-
ival probability, clearly demonstrate the feasibility of simplifying
he AVA booster schedule. We  conclude based on these data and
nalyses that a 3-IM priming series with a 3-year booster (4-IM), or
ith an initial booster at 1 year and a subsequent 2-year interval
5-IM) are both viable alternatives to the current AVA prime-boost
chedule for pre-exposure prophylaxis against anthrax.
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